Publications by authors named "L Almenar-Bonet"
Heart transplantation (HT) is the gold standard therapy for advanced heart failure (ADHF), and LVADs as destination therapy are an option in non-HT candidates. Most patients with ADHF never receive HT or an LVAD, so alternative strategies are needed. Intermittent levosimendan can reduce HF hospitalizations in ADHF patients in the short term.
View Article and Find Full Text PDFBackground: A high percentage of patients with congenital heart diseases (CHD) reach adulthood and, over time, require heart transplantation (HTx) or combined heart-lung transplantation (HLTx). Among CHD, there are subgroups associated with a higher risk.
Methods: Retrospective analysis of HTx and HLTx in CHD patients.
Introduction: Currently, there is little evidence on the prevalence and factors associated with sarcopenia risk or frailty risk in patients post heart transplantation (HTx). The objective of this study was to analyze the influence of sociodemographic, lifestyle, physical, and psychological factors on sarcopenia and frailty risk in patients post-HTx.
Methods: 133 patients post-HTx (59.
Article Synopsis
- The study examines the effectiveness and safety of ultrafiltration (UF) compared to traditional diuretic therapy in treating cardiac decompensation associated with cardiorenal syndrome (CRS), especially when diuretics yield poor results.
- Analyzed data from 13 studies involving around 1,100 patients showed that UF had better trends in reducing creatinine and facilitating greater weight loss and fluid removal compared to diuretics, without impacting mortality or hospital stay durations significantly.
- The findings suggest that UF could be a beneficial alternative for patients not responding well to diuretics, potentially lowering readmission rates, though further prospective studies are necessary to confirm these benefits.